The development of biologics is still a young branch of the medical and pharmaceutical field. Further research and a wider usage of these substances will be necessary to fully explore their potential. Only by continuously expanding our knowledge about disease driving molecules and the pathomechanisms involved will science be able to extend the field of biological therapy. In fact, the application of biologics has in itself already unraveled new insights into disease processes.
Clearly it is not within the scope of this book to evaluate the chances of even more advanced drug systems on the verge of clinical use, e.g., immune liposomes carrying highly active small molecules to the targets presently covered by biologics or nanoparticles targeting gene activity modifiers. Biologics are already widely recognized as milestones in the history of pharmacology. In the near future we will learn whether they will accompany us for long, as many think, or - as others feel - they will soon leave the stage like dinosaurs and be succeeded by those small molecules. More likely, particularly successful biologics will be applied more widely, will become more affordable and will be here to stay. In this case, this kind of textbook will be only the first of a continuing series
Development and Pre-clinical Pharmacology I of Biologics
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.